Report of Foreign Issuer (6-k)
29 September 2020 - 9:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of September 2020
Commission File Number: 001-37452
CELYAD ONCOLOGY SA
(Translation of registrants name into English)
Rue Edouard
Belin 2
1435 Mont-Saint-Guibert, Belgium
(Address of principal executive offices)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Celyad Oncology SA
On September 29, 2020, Celyad Oncology SA (the Company) issued a press release announcing that the Company has entered into a Clinical
Trial Collaboration and Supply Agreement (the Collaboration Agreement) with MSD International GmbH, a subsidiary of Merck & Co., Inc. (Merck). Pursuant to the Collaboration Agreement, the Company will
conduct the Phase 1b KEYNOTE-B79 clinical trial, which will evaluate the Companys investigational non-gene edited allogeneic
CAR-T candidate, CYAD-101, following FOLFIRI (combination of 5-fluorouracil, leucovorin and irinotecan) preconditioning
chemotherapy, with Mercks anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in refractory metastatic colorectal
cancer patients with microsatellite stable, mismatch-repair proficient disease. The extent of the collaboration between the parties is limited to the drug supply support and execution of the clinical trial, each as described in the Collaboration
Agreement.
A copy of the Companys press release is attached hereto as Exhibit 99.1, which is incorporated herein by reference.
The information contained in this Current Report on Form 6-K, including Exhibit 99.1, except for the
quote of Filippo Petti contained in Exhibit 99.1, is hereby incorporated by reference into the Companys Registration Statements on Forms F-3 (File No. 333-248464) and S-8 (File No. 333-220737).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
CELYAD ONCOLOGY SA
|
|
|
|
Date: September 29, 2020
|
|
By:
|
|
/s/ Filippo Petti
|
|
|
|
|
Filippo Petti
|
|
|
|
|
Chief Executive Officer and Financial Officer
|
Celyad Oncology (NASDAQ:CYAD)
Historical Stock Chart
From Apr 2024 to May 2024
Celyad Oncology (NASDAQ:CYAD)
Historical Stock Chart
From May 2023 to May 2024